Efficacy Of Albendazole Against Fascioliosis And Its Effects On Sgot, Sgpt And Serum Bilirubin In Buffaloes
By: Dilshad Hussain
| Prof.Dr.Muhammad Ashraf.
Contributor(s): Manzoor | Muhammed Sarwer Khan | Faculty of Veterinary Sciences.
Material type: 
BookPublisher: 1992Subject(s): Department of Clinical Medicine & SurgeryDDC classification: 0318,T Dissertation note: Fascioliasis causes great losses in buffaloes, if not treated. This study was designed to determine the efficacy of an anthelmintic, albendazole against the disease. The effects of the drug on serum bilirubin, SOOT and SGPT were also determined. For this purpose, 250 suspected buffaloes were selected and out of which forty positive cases having EPG above 200 were taken as infected group. The infected group was further divided into two equal groups C and D. Group C served as infected untreated control and group D was treated with albendazole. Similarly, forty healthy animals were divided into two equal groups A and B. The group A served as healthy untreated control while group B was treated with albendazole. All the animals were examined on zero day, 7th day and 14th day for the SOOT, SGPT and serum bilirubin. The ova counts per gram of faeces was performed only in infected groups on zero day, 7th day and 14th day.
Albendazole (Valbazen - SK&F) was 49.2 % effective on 7th day post-medication and 84.2 % effective on 14th day post- medication. The drug had no effect on SGOT, SGPT and serum bilirubin in healthy animals which indicated that it was non toxic at its terapeutic dosage level of 10 mg/kg body weight. The drug had positive effect on SGOT,SGPT and serum bilirubin through lowering their levels in infected animals on 7th day and 14th day post-medication at dosage rate of 10 mg/kg body weight. No side effects were observed in any animals during the experiment. Hence, albendazole (Valbazen) was concluded to be the effective and safe drug against fascioliasis in buffaloes at its therapeutic dosage level of 10 mg/kg body weight.
| Item type | Current location | Collection | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|---|
Thesis
|
UVAS Library Thesis Section | Veterinary Science | 0318,T (Browse shelf) | Available | 0318,T |
Browsing UVAS Library Shelves , Shelving location: Thesis Section , Collection code: Veterinary Science Close shelf browser
Fascioliasis causes great losses in buffaloes, if not treated. This study was designed to determine the efficacy of an anthelmintic, albendazole against the disease. The effects of the drug on serum bilirubin, SOOT and SGPT were also determined. For this purpose, 250 suspected buffaloes were selected and out of which forty positive cases having EPG above 200 were taken as infected group. The infected group was further divided into two equal groups C and D. Group C served as infected untreated control and group D was treated with albendazole. Similarly, forty healthy animals were divided into two equal groups A and B. The group A served as healthy untreated control while group B was treated with albendazole. All the animals were examined on zero day, 7th day and 14th day for the SOOT, SGPT and serum bilirubin. The ova counts per gram of faeces was performed only in infected groups on zero day, 7th day and 14th day.
Albendazole (Valbazen - SK&F) was 49.2 % effective on 7th day post-medication and 84.2 % effective on 14th day post- medication. The drug had no effect on SGOT, SGPT and serum bilirubin in healthy animals which indicated that it was non toxic at its terapeutic dosage level of 10 mg/kg body weight. The drug had positive effect on SGOT,SGPT and serum bilirubin through lowering their levels in infected animals on 7th day and 14th day post-medication at dosage rate of 10 mg/kg body weight. No side effects were observed in any animals during the experiment. Hence, albendazole (Valbazen) was concluded to be the effective and safe drug against fascioliasis in buffaloes at its therapeutic dosage level of 10 mg/kg body weight.
There are no comments for this item.